Quest Diagnostics (DGX) Tops Q3 EPS by 3c; raises guidance

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $2.22, $0.03 better than the analyst estimate of $2.19. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.27 billion.

GUIDANCE:

Quest Diagnostics sees FY2023 EPS of $8.65-$8.75, versus the consensus of $8.71. Quest Diagnostics sees FY2023 revenue of $9.19-9.24 billion, versus the consensus of $9.18 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Rithm Capital earns S&P upgrade to ’B+’ following steady revenue diversification
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance